Clinical Trial Update: A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms [Phase 1]

View source ↗

Summary

The Phase 1 study of TAS1553 in subjects with relapsed or refractory acute myeloid leukemia and other myeloid neoplasms has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Myeloproliferative Neoplasms
• Myeloproliferative Neoplasm

Drugs mentioned

• TAS1553

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Acute Myeloid Leukemia, Myeloproliferative Neoplasm | Phase 1 | Status: TERMINATED